XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities      
Net (loss) income $ (314,248) $ (181,223) $ 29,403
Adjustments to reconcile net loss to net cash used in operating activities      
Loss (gain) from Continuation Advances   52,000 (34,000)
Depreciation 9,480 7,199 6,428
Amortization of intangible 913 381  
Amortization of right-of-use assets 6,925 4,005 2,876
Amortization of debt discount and financing costs 640 539 129
Share-based compensation 78,613 73,355 17,533
Amortization of premium and accretion of discount on marketable securities, net (244) 4,011 (107)
Change in the estimated fair value of contingent consideration 2,377 1,143  
Inventory provision 6,027 678 527
Loss on disposition of equipment 278 54  
Deferred income taxes   (93,649)  
Changes in assets and liabilities      
Accounts receivable, net 5,455 (7,166) (1,603)
Inventory, net (33,906) (13,109) (1,623)
Prepaid expenses and other assets (12,324) (1,024) (1,063)
Accounts payable 1,025 6,363 (5,072)
Accrued expenses (3,651) 15,320 4,102
Deferred revenue (3,734) 25,736 729
Operating lease liabilities (7,724) (4,990) (3,802)
Other liabilities 887 (803) 5,046
Net cash (used in) provided by operating activities (263,211) (111,180) 19,503
Cash flows from investing activities      
Purchase of property and equipment (16,750) (5,931) (1,039)
Addition of intangible assets (179)    
Purchase of investments (442,788) (988,046) (373,283)
Sales of investments   212,734 1,400
Maturities of investments 575,800 422,505 153,600
Net cash provided by (used in) investing activities 116,083 (678,531) (219,322)
Cash flows from financing activities      
Continuation Advances   (52,000) 34,000
Proceeds from issuance of Convertible Senior Notes, net of issuance costs   895,536  
Proceeds from issuance of common stock under equity offerings, net of issuance costs   294,845 187,479
Proceeds from issuance of common stock from equity plans 11,230 31,806 46,360
Notes payable principal payoff (1,608) (361) (16,000)
Other   (245)  
Net cash provided by financing activities 9,622 1,169,581 251,839
Net (decrease) increase in cash, cash equivalents, and restricted cash (137,506) 379,870 52,020
Cash, cash equivalents, and restricted cash at beginning of period 465,817 85,947 33,927
Cash, cash equivalents, and restricted cash at end of period 328,311 465,817 85,947
Cash and cash equivalents at end of period 325,089 460,725 81,611
Restricted cash at end of period 3,222 5,092 4,336
Supplemental disclosure of cash flow information      
Interest Paid 14,049 6,928 491
Supplemental disclosure of non-cash investing and financing activities      
Inventory transferred to property and equipment 2,812 2,586 1,097
Property and equipment transferred to inventory $ (715) (383) $ (919)
Right-of-use asset and liability additions and modifications   2,576  
Issuance of common stock in acquisition of Omniome   237,885  
Circulomics, Inc [Member]      
Cash flows from investing activities      
Cash paid for purchase of business acquisition, net of cash acquired   (28,560)  
Omniome, Inc [Member]      
Cash flows from investing activities      
Cash paid for purchase of business acquisition, net of cash acquired   $ (291,233)